EGFR and ovarian cancer: In the present study, we successfully enriched ovarian cancer stem-like cells and demonstrated that AREG promotes ovarian cancer stemness and drug resistance via the AREG-EGFR-ERK pathway and that miR-34c-5p targets AREG to inhibit ovarian cancer stemness and drug resistance.